Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Telix PharmaceuticalsASX:TLX -4.96%59 Cash-to-Debt is 0.43 as of Jun. 2026, which is 96% below its 10-year median of 11.14. GuruFocus rates ASX:TLX with a GF Score™ of 59/100 and a GF Value™ of A$36.74 (Possible Value Trap). The stock has 7 warning signs investors should review. Among 1,395 Biotechnology companies, Telix Pharmaceuticals ranks worse than 86.16% on this metric.
Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Telix Pharmaceuticals's cash to debt ratio for the quarter that ended in Jun. 2026 was 0.43.
If Cash to Debt ratio is less than 1, the company cannot pay off its debt using the cash in hand. Here we can see, Telix Pharmaceuticalscouldn't pay off its debt using the cash in hand for the quarter that ended in Jun. 2026.
The historical rank and industry rank for Telix Pharmaceuticals's Cash-to-Debt or its related term are showing as below:
ASX:TLX'
s Cash-to-Debt Range Over the Past 10 Years
Min: 0.3 Med: 11.14 Max: No Debt
Current: 0.43
During the past 8 years, Telix Pharmaceuticals's highest Cash to Debt Ratio was No Debt. The lowest was 0.30. And the median was 11.14.
ASX:TLX's Cash-to-Debt is ranked worse than 86.16% of 1395
companies
in the Biotechnology industry
Industry Median: 7.17
vs ASX:TLX: 0.43
If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.
Telix Pharmaceuticals Cash-to-Debt Related Terms
Telix Pharmaceuticals Cash-to-Debt Historical Data
* Premium members only.
The historical data trend for Telix Pharmaceuticals's Cash-to-Debt can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
ASX:TLX vs VRTX, REGN, MRNA: Cash-to-Debt Comparison
For the Biotechnology subindustry, Telix Pharmaceuticals's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Telix Pharmaceuticals Cash-to-Debt vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Telix Pharmaceuticals's Cash-to-Debt distribution charts can be found below:
* The bar in red indicates where Telix Pharmaceuticals's Cash-to-Debt falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Telix Pharmaceuticals (ASX:TLX) has a Cash-to-Debt of 0.43 as of Jun. 2026. This is 96% below median its historical median of 11.14. Over the past decade, Telix Pharmaceuticals' Cash-to-Debt has ranged from 0.30 to 10,000.00. According to the industry distribution chart, Telix Pharmaceuticals ranks #1202 out of 1395 companies in the Biotechnology industry, placing it in the top 86.2%.
Is Telix Pharmaceuticals' Cash-to-Debt too high?
Telix Pharmaceuticals' current Cash-to-Debt of 0.43 is 96% below median its 10-year median of 11.14. Over the past 10 years, this metric has ranged from a low of 0.30 to a high of 10,000.00. The Biotechnology industry median Cash-to-Debt is 7.17. Telix Pharmaceuticals' value of 0.43 is 94% below this industry median. Based on the distribution chart, Telix Pharmaceuticals ranks #1202 out of 1395 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Telix Pharmaceuticals has a GF Score™ of 59/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Telix Pharmaceuticals' Cash-to-Debt compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Telix Pharmaceuticals ranks #1202 out of 1395 companies for Cash-to-Debt. This places Telix Pharmaceuticals in the lower half of its industry. The industry median Cash-to-Debt is 7.17. Telix Pharmaceuticals' value of 0.43 is 94% below this benchmark. Historically, Telix Pharmaceuticals' own Cash-to-Debt has ranged from 0.30 to 10,000.00 over the past decade. While the company's 10-year median is 11.14 vs. the industry median of 7.17, Telix Pharmaceuticals has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash-to-Debt for a Biotechnology company?
The median Cash-to-Debt among Biotechnology companies is 7.17, based on 1,395 companies in the industry. Companies in the top quartile (top 25%) have a Cash-to-Debt significantly above this median, while those in the bottom quartile fall well below. However, Cash-to-Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Telix Pharmaceuticals's current Cash-to-Debt of 0.43 is 94% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash-to-Debt mean?
A high Cash-to-Debt can signal that a stock is expensive relative to its fundamentals. For the Biotechnology industry, the median Cash-to-Debt is 7.17 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Telix Pharmaceuticals's current Cash-to-Debt is 0.43, which is 96% below median its own 10-year median of 11.14. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Telix Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Telix Pharmaceuticals (ASX:TLX) is currently considered Possible Value Trap. The stock's GF Value™ is A$36.74, compared to a current price of A$16.87 — trading 54.1% below its estimated fair value. The current Cash-to-Debt is 0.43, which is 96% below median its 10-year median of 11.14 and 94% below the Biotechnology industry median of 7.17. Telix Pharmaceuticals' overall GF Score™ is 59/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash-to-Debt calculated?
Cash-to-Debt is calculated from a company's financial statements. For Telix Pharmaceuticals (ASX:TLX), the current Cash-to-Debt is 0.43 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Telix Pharmaceuticals (ASX:TLX) Overvalued in 2026?
Based on GuruFocus' analysis, Telix Pharmaceuticals stock appears to be undervalued.
The current stock price of A$16.87 is trading 54.1% below its estimated GF Value™ of A$36.74.
GuruFocus considers Telix Pharmaceuticals to be Possible Value Trap.
Key valuation signals for ASX:TLX:
Cash-to-Debt: 0.43 (96% below median its 10-year median of 11.14)
GF Value™: A$36.74 vs. price of A$16.87 (54.1% below fair value)
Industry Position: 94% below the Biotechnology median (#1202 of 1395)
No single metric tells the full story. See the ASX:TLX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Telix develops radiopharmaceuticals to manage cancer. Radiopharmaceuticals are radioisotopes bound to molecules that can target specific cells. At low doses, these drugs can bind to specific cancer cells with radiation, and then positron emission tomography imaging can accurately visualize tumors. At high doses, these drugs can selectively target and treat tumors with radiation, known as radioligand therapy. Radiopharmaceuticals are usually injected into the bloodstream. Telix has a pipeline of potential radiopharmaceuticals but currently earns most of its revenue from US sales of Illuccix, largely used as an imaging agent to visualize the spread of prostate cancer.
59GF Score
Get the complete analysis for ASX:TLX
Cash-to-Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:TLX has been successfully added to your 
